Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2019-2023
SKU ID : TNV-14253023 | Publishing Date : 08-May-2019 | No. of pages : 118
Detailed TOC of Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY TYPE
Market segmentation by type
Comparison by type
Second-generation ALK inhibitors - Market size and forecast 2018-2023
First-generation ALK inhibitors - Market size and forecast 2018-2023
Third-generation ALK inhibitors - Market size and forecast 2018-2023
Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
F. Hoffmann-La Roche Ltd.
Novartis AG
Pfizer Inc.
Takeda Pharmaceutical Co. Ltd.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Type - Market share 2018-2023 (%)
Exhibit 18: Comparison by type
Exhibit 19: Second-generation ALK inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Second-generation ALK inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 21: Second-generation ALK inhibitors pipeline
Exhibit 22: First-generation ALK inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Upcoming patent expiry of XALKORI
Exhibit 24: First-generation ALK inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 25: Third-generation ALK inhibitors - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Lorlatinib pipeline
Exhibit 27: Third-generation ALK inhibitors - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by type
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in North America
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Patient assistance programs
Exhibit 47: Alternative therapies for oncology conditions
Exhibit 48: Side effects of ALK inhibitors
Exhibit 49: Impact of drivers and challenges
Exhibit 50: Drugs with respect to their expanded indications
Exhibit 51: Vendor landscape
Exhibit 52: Landscape disruption
Exhibit 53: Vendors covered
Exhibit 54: Vendor classification
Exhibit 55: Market positioning of vendors
Exhibit 56: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 57: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 58: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 59: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 60: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 61: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 62: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 63: Novartis AG - Vendor overview
Exhibit 64: Novartis AG - Business segments
Exhibit 65: Novartis AG - Organizational developments
Exhibit 66: Novartis AG - Geographic focus
Exhibit 67: Novartis AG - Segment focus
Exhibit 68: Novartis AG - Key offerings
Exhibit 69: Novartis AG - Key customers
Exhibit 70: Pfizer Inc. - Vendor overview
Exhibit 71: Pfizer Inc. - Business segments
Exhibit 72: Pfizer Inc. - Organizational developments
Exhibit 73: Pfizer Inc. - Geographic focus
Exhibit 74: Pfizer Inc. - Segment focus
Exhibit 75: Pfizer Inc. - Key offerings
Exhibit 76: Pfizer Inc. - Key customers
Exhibit 77: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 78: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 79: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 83: Validation techniques employed for market sizing
Exhibit 84: Definition of market positioning of vendors
Keyplayers in Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2019-2023
F. Hoffmann-La Roche Ltd.Novartis AG
Pfizer Inc.
Takeda Pharmaceutical Co. Ltd.